VTRS · Full Picture

Viatris Inc — the full picture

Earnings window · 2026-07-16 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 90
    +102.3% net_income (realized); 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); structured_verified
    Combined summarized revenues and gross profit were $— and $— respectively for the six months ended June 30, 2026 and for the year ended December 31, 2025; loss from operations was $(591.7) for the six months ended June 30, 2026 and $(1,008.2) for the year ended December 31, 2025; net earnings (loss) were $57.6 for the six months ended June 30, 2026 and $(3,514.9) for the year ended December 31, 2025.
  2. Headcount / Restructuring · Restructuring & impairmentPriority 80
    -18.6% operating_income; 4 forward row(s); quote_verified
    The Company expects to incur total pre-tax charges for the committed restructuring activities ranging between $700 million and $850 million.
  3. Other Income (Expense), Net · UnclassifiedPriority 77
    +23.1% net_income (realized); structured_verified
    Other (income) expense, net for the three months ended June 30, 2026 totaled $50.4 million of income, compared to $333.5 million of expense for the three months ended June 30, 2025, a change of $383.9 million, primarily driven by a prior year loss of $284.0 million on changes in fair value of CCPS in Biocon Biologics and a current year gain of $56.3 million on changes in fair value of Biocon equity shares.
  4. Product Launch and Transition · Products & launchesPriority 77
    +6.7% revenue; 2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
    The Company expects to deliver approximately $450 million to $550 million in new product revenues in full-year 2026
  5. Manufacturing and Supply Disruptions · UnclassifiedPriority 76
    -1.7% revenue; 3 sources (news, sec_filing, transcript); 2 forward row(s); structured_verified
    The temporary manufacturing suspension due to the Nashik fire and intermittent disruptions are expected to impact product supply in the second half of the year and are currently anticipated to impact total revenues between $100 million and $150 million in the second half of 2026.
  6. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 73
    +0.9% cash; 4 sources (news, press_release, sec_filing, transcript); 7 forward row(s); structured_verified
    In December 2025, Biocon acquired all of Viatris’ CCPS in Biocon Biologics for total consideration of $815.0 million, consisting of $400.0 million in cash and $415.0 million in newly issued equity shares of Biocon.
  7. Guidance and Outlook · Guidance & outlookPriority 73
    3 sources (news, press_release, transcript); 12 forward row(s); quote_verified
    Viatris reported 3.5% operational year-over-year revenue growth in Q2 2026 and raised its full-year guidance.
  8. Gross Margin Drivers · Gross marginPriority 71
    -9.8% net_income (realized); 3 sources (press_release, sec_filing, transcript); structured_verified
    Purchase accounting amortization (primarily included in cost of sales) for the three months ended June 30, 2026 was $586.4 million and for the three months ended June 30, 2025 was $597.8 million; for the six months ended June 30, 2026 was $1,177.9 million and for the six months ended June 30, 2025 was $1,181.3 million.
  9. Accrued Legal and Regulatory · Regulatory action & investigationsPriority 68
    -6.6% operating_income (realized); 1 forward row(s); structured_verified
    Litigation settlements and other contingencies, net for the six months ended June 30, 2026 totaled $126.7 million, compared to $(121.1) million for the six months ended June 30, 2025; contingent consideration adjustment was $105.7 million and litigation settlements, net were $21.0 million for the six months ended June 30, 2026.
  10. Capital Return Program · Buybacks & dividendsPriority 66
    -4.1% cash (realized); 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); structured_verified
    The Company has approximately $730 million remaining under its existing board-authorized share repurchase program
  11. Free Cash Flow and Liquidity · UnclassifiedPriority 66
    2 sources (press_release, transcript); 2 forward row(s); quote_verified
    Reconciliation shows estimated 2026 Free Cash Flow of $1,450 - $1,750 after $350 - $450 of capital expenditures, and Free Cash Flow excluding transaction and restructuring costs of $2,050 - $2,350 after adding ~ $600 estimated transaction-related and restructuring-related costs
  12. Liquidity and Debt Position · Debt, leverage & refinancingPriority 65
    -6.6% assets (realized); structured_verified
    Net cash used in financing activities was $1.45 billion for the six months ended June 30, 2026, compared to $829.4 million for the six months ended June 30, 2025, an increase of $617.0 million.

Threads by pillar

Revenue & Demand Priority 96 · 7 threads

Costs & Margins Priority 91 · 8 threads

Capital & Balance Sheet Priority 88 · 8 threads

Strategy & Portfolio Priority 77 · 3 threads

Legal, Regulatory & Policy Priority 78 · 5 threads

Guidance & Outlook Priority 73 · 1 thread

Macro & Market Conditions Priority 71 · 4 threads

Management & Governance Priority 30 · 1 thread

Unclassified Priority 91 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-18.6%+18.6%-25.4%
revenue+3.5%+10.1%+27.9%
cash-1.4%+3.2%-4.8%
net_income-0.6%+0.6%+97.8%
assets-0.1%+0.1%-6.9%
margin——+3.0%
liability——+5.3%